Philippe Martiat

7.3k citations
110 papers · 5.6k indexed · 2 hit papers · h-index 38

Impact in

  • Hematology top 0.5%
    • Chronic Myeloid Leukemia Treatments
    • Acute Myeloid Leukemia Research
  • Genetics top 0.5%
    • Chronic Lymphocytic Leukemia Research
    • Mesenchymal stem cell research

Papers in

    • Chronic Lymphocytic Leukemia Research 34
    • Chronic Myeloid Leukemia Treatments 27
    • Acute Myeloid Leukemia Research 20
    • Hematopoietic Stem Cell Transplantation 14

Philippe Martiat

109 papers receiving 5.4k citations

Hit Papers

Prevalence, determinants, and outcomes of nonadherence to imatinib therapy in patients with chronic myeloid leukemia: the ADAGIO study 2009 · 463 citations
463200320262010201850010001.5k

Peers

Philippe Martiat
Comparison fields: 5 of 121
  • Hematology 1.6k
  • Genetics 1.4k
  • Cancer Research 1.5k
  • Family Practice 127
  • Oncology 1.3k
Replace Justus Duyster with:
Justus Duyster Germany
Antonio Palumbo Italy
Martin F. Fey Switzerland
Didier Bouscary France
Markus Y. Mapara United States
Joseph O. Moore United States
Torben Plesner Denmark
Martin Höglund Sweden
Xavier Leleu France
Javier Pinilla‐Ibarz United States
Philippe Martiat relative to Justus Duyster Germany Justus Duyster's profile →
Citations per field
00.5×10×15×21.2×
Justus Duyster · 1×
Citations per year

Countries citing papers authored by Philippe Martiat

Since Specialization
Citations

This map shows the geographic impact of Philippe Martiat's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Philippe Martiat with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Philippe Martiat more than expected).

Fields of papers citing papers by Philippe Martiat

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Philippe Martiat. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Philippe Martiat. The network helps show where Philippe Martiat may publish in the future.

Co-authors

The 25 scholars most cited alongside Philippe Martiat, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Philippe Martiat Line = papers co-authored together Philippe Martiat links everyone, so they are left out of the graph.

All Works

20 of 20 papers shown
#Work
1 2013140
2 201010
3
Microrna-29c and 223 and Their Prognostic Value in Chronic Lymphocytic Leukemia
20091
4 2009188
5
Reduced Intensity Conditioning Hematopoietic Stem Cell Transplantation (HSCT) with Mesenchymal Stromal Cell (MSC) infusion for the Treatment of Metachromatic Leukodystrophy (MLD): A case report
20087
6 200735
7
Four genes by RT-PCR predicts distant relapse for women given adjuvant tamoxifen
20052
8 200452
9
Phase I-II study of a Farnesyl Transferase Inhibitor (FTI), SCH66336, in patients with myelodysplastic syndrome (MDS) or secondary acute myeloid leukemia (sAML).
20027
10 20022
11 200045
12 199918
13
Peripheral blood stem cells contamination in diffuse large cell (DLCL) and mantle cell (MCL) lymphomas: A quantitative comparison.
19980
14
Detection of residual disease by immunostaining of bone marrow trephines (BMT) after 2-chlorodeoxyadenosine (CDA) in previously untreated chronic lymphocytic leukemia (CLL).
19951
15
Cyclosporine-a (cy A) Has Only Marginal Antileukemic Activity in Refractory Chronic Lymphocytic-leukemia (cll)
19941
16
2-chlorodeoxyadenosine (cda) for Previously Untreated Chronic Lymphocytic-leukemia (cll)
19943
17
2-chloro-deoxyadenosine With Or Without Daunorubicin for Relapsing Or Refractory Acute Myeloblastic-leukemia
19931
18
2-chlorodeoxyadenosine Therapy in Non-hodgkins-lymphoma
19932
19
A Single Course of 2-chloro-deoxyadenosine (2-cda) Does Not Eradicate Leukemic-cells in Hairy-cell Leukemia (hcl) Patients Achieving Complete Remission
19933
20 199018

About Philippe Martiat

Philippe Martiat is a scholar working on Genetics, Hematology, Immunology, Pathology and Forensic Medicine and Agronomy and Crop Science, having authored 110 papers that have together received 5.6k indexed citations. Recurring topics across this work include Chronic Lymphocytic Leukemia Research (34 papers), Chronic Myeloid Leukemia Treatments (27 papers), Acute Myeloid Leukemia Research (20 papers), Hematopoietic Stem Cell Transplantation (14 papers), Immune Cell Function and Interaction (14 papers), Acute Lymphoblastic Leukemia research (14 papers), Lymphoma Diagnosis and Treatment (14 papers) and T-cell and Retrovirus Studies (9 papers). The work is most often cited by research in Hematology (1.6k citations), Genetics (1.4k citations), Cancer Research (1.5k citations), Family Practice (127 citations) and Oncology (1.3k citations). Philippe Martiat has collaborated with scholars based in Belgium, United Kingdom and France. Frequent co-authors include Adrian L. Harris, Christos Sotiriou, Stephen B. Fox, Amir A. Jazaeri, Lisa M. McShane, Soek-Ying Neo, Philip M. Long, Edison T. Liu, Edward L. Korn and Dominique Bron. Their work appears in journals such as Blood, British Journal of Haematology, Annals of Hematology, Haematologica and Journal of Translational Medicine.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Rankless by CCL
2026